RU2008135764A - PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CERVICAL DYSPLASTIC PROCESSES - Google Patents

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CERVICAL DYSPLASTIC PROCESSES Download PDF

Info

Publication number
RU2008135764A
RU2008135764A RU2008135764/15A RU2008135764A RU2008135764A RU 2008135764 A RU2008135764 A RU 2008135764A RU 2008135764/15 A RU2008135764/15 A RU 2008135764/15A RU 2008135764 A RU2008135764 A RU 2008135764A RU 2008135764 A RU2008135764 A RU 2008135764A
Authority
RU
Russia
Prior art keywords
suppository
epigallocatechin
gallate
drug according
treatment
Prior art date
Application number
RU2008135764/15A
Other languages
Russian (ru)
Other versions
RU2395281C2 (en
Inventor
Всеволод Иванович Киселев (RU)
Всеволод Иванович Киселев
Original Assignee
Всеволод Иванович Киселев (RU)
Всеволод Иванович Киселев
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Всеволод Иванович Киселев (RU), Всеволод Иванович Киселев filed Critical Всеволод Иванович Киселев (RU)
Priority to RU2008135764/15A priority Critical patent/RU2395281C2/en
Priority to EA201100417A priority patent/EA018383B1/en
Priority to UAA201011132A priority patent/UA95583C2/en
Priority to PCT/RU2009/000412 priority patent/WO2010027294A1/en
Publication of RU2008135764A publication Critical patent/RU2008135764A/en
Application granted granted Critical
Publication of RU2395281C2 publication Critical patent/RU2395281C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1. Лекарственное средство для лечения диспластических процессов шейки матки и слизистой прямой кишки в форме суппозитория, характеризующееся тем, что содержит 3,3'-дииндолилметан, эпигаллокатехин-3-галлат, а также катализатор ингибирующей активности эпигаллокатехин-3-галлата в отношении ДНК-метилтрансфераз, представляющий собой катионы Mg2+ в виде фармацевтически приемлемой соли магния, липофильную основу, содержащую твердый жир, поливинилпирролидон и бутилгидроксианизол и/или бутилгидрокситолуол при следующем содержании, мас.%: ! 3,3'-Дииндолилметан1,0-10,0Эпигаллокатехин-3-галлат1,0-8,0Поливинилпирролидон0,5-1,2Бутилгидроксианизол0,3-0,5Соль магния0,1-2,0Липофильная основаОстальное ! 2. Лекарственное средство по п.1, характеризующееся тем, что указанный суппозиторий представляет собой вагинальный суппозиторий. ! 3. Лекарственное средство по п.1, характеризующееся тем, что указанный суппозиторий представляет собой ректальный суппозиторий. ! 4. Лекарственное средство по любому из пп.1-3, характеризующееся тем, что катализатор ингибирующей активности эпигаллокатехин-3-галлата в отношении ДНК-метилтрансфераз представляет собой магний хлористый.1. A drug for the treatment of dysplastic processes of the cervix and rectal mucosa in the form of a suppository, characterized in that it contains 3,3'-diindolylmethane, epigallocatechin-3-gallate, as well as a catalyst for the inhibitory activity of epigallocatechin-3-gallate in relation to DNA- methyltransferase, which is a Mg2 + cation in the form of a pharmaceutically acceptable magnesium salt, a lipophilic base containing solid fat, polyvinylpyrrolidone and butylhydroxyanisole and / or butylhydroxytoluene with the following content, wt.%:! 3.3'-Diindolylmethane 1.0-10.0 Epigallocatechin-3-gallate 1.0-8.0 Polyvinylpyrrolidone 0.5-1.2 Butyl hydroxyanisole 0.3-0.5 Magnesium salt 0.1-2.0 Lipophilic base 2. The drug according to claim 1, characterized in that the suppository is a vaginal suppository. ! 3. The drug according to claim 1, characterized in that the suppository is a rectal suppository. ! 4. The drug according to any one of claims 1 to 3, characterized in that the catalyst for the inhibitory activity of epigallocatechin-3-gallate in relation to DNA methyltransferases is magnesium chloride.

Claims (4)

1. Лекарственное средство для лечения диспластических процессов шейки матки и слизистой прямой кишки в форме суппозитория, характеризующееся тем, что содержит 3,3'-дииндолилметан, эпигаллокатехин-3-галлат, а также катализатор ингибирующей активности эпигаллокатехин-3-галлата в отношении ДНК-метилтрансфераз, представляющий собой катионы Mg2+ в виде фармацевтически приемлемой соли магния, липофильную основу, содержащую твердый жир, поливинилпирролидон и бутилгидроксианизол и/или бутилгидрокситолуол при следующем содержании, мас.%:1. A drug for the treatment of dysplastic processes of the cervix and rectal mucosa in the form of a suppository, characterized in that it contains 3,3'-diindolylmethane, epigallocatechin-3-gallate, as well as a catalyst for the inhibitory activity of epigallocatechin-3-gallate in relation to DNA- methyltransferase, which is a Mg2 + cation in the form of a pharmaceutically acceptable magnesium salt, a lipophilic base containing solid fat, polyvinylpyrrolidone and butylhydroxyanisole and / or butylhydroxytoluene with the following content, wt.%: 3,3'-Дииндолилметан3,3'-Diindolylmethane 1,0-10,01.0-10.0 Эпигаллокатехин-3-галлатEpigallocatechin-3-gallate 1,0-8,01.0-8.0 ПоливинилпирролидонPolyvinylpyrrolidone 0,5-1,20.5-1.2 БутилгидроксианизолButylhydroxyanisole 0,3-0,50.3-0.5 Соль магнияMagnesium salt 0,1-2,00.1-2.0 Липофильная основаLipophilic base ОстальноеRest
2. Лекарственное средство по п.1, характеризующееся тем, что указанный суппозиторий представляет собой вагинальный суппозиторий.2. The drug according to claim 1, characterized in that the suppository is a vaginal suppository. 3. Лекарственное средство по п.1, характеризующееся тем, что указанный суппозиторий представляет собой ректальный суппозиторий.3. The drug according to claim 1, characterized in that the suppository is a rectal suppository. 4. Лекарственное средство по любому из пп.1-3, характеризующееся тем, что катализатор ингибирующей активности эпигаллокатехин-3-галлата в отношении ДНК-метилтрансфераз представляет собой магний хлористый. 4. The drug according to any one of claims 1 to 3, characterized in that the catalyst for the inhibitory activity of epigallocatechin-3-gallate in relation to DNA methyltransferases is magnesium chloride.
RU2008135764/15A 2008-09-04 2008-09-04 Pharmaceutical composition for treatment of dysplastic processes of cervix RU2395281C2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
RU2008135764/15A RU2395281C2 (en) 2008-09-04 2008-09-04 Pharmaceutical composition for treatment of dysplastic processes of cervix
EA201100417A EA018383B1 (en) 2008-09-04 2009-08-18 Composition for treating dysplastic changes in the uterine cervix
UAA201011132A UA95583C2 (en) 2008-09-04 2009-08-18 Composition for treatment of displastic processes of uterine cervix
PCT/RU2009/000412 WO2010027294A1 (en) 2008-09-04 2009-08-18 Composition for treating dysplastic changes in the uterine cervix

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2008135764/15A RU2395281C2 (en) 2008-09-04 2008-09-04 Pharmaceutical composition for treatment of dysplastic processes of cervix

Publications (2)

Publication Number Publication Date
RU2008135764A true RU2008135764A (en) 2010-03-10
RU2395281C2 RU2395281C2 (en) 2010-07-27

Family

ID=41797309

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008135764/15A RU2395281C2 (en) 2008-09-04 2008-09-04 Pharmaceutical composition for treatment of dysplastic processes of cervix

Country Status (4)

Country Link
EA (1) EA018383B1 (en)
RU (1) RU2395281C2 (en)
UA (1) UA95583C2 (en)
WO (1) WO2010027294A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2456987C1 (en) * 2011-03-21 2012-07-27 Сергей Владимирович Енгашев Method for producing gelatine capsules of 3,31-diindolylmethane

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2454232C2 (en) * 2010-09-16 2012-06-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН) Application of triindolyl methane derivatives as anticancer drugs
GB2533381A (en) * 2014-12-18 2016-06-22 Nordic Labs Ltd Novel treatment of STIs
RU2601621C2 (en) * 2015-03-18 2016-11-10 Общество с ограниченной ответственностью "Фармацевтический завод иммунных лекарственных средств" Sodium deoxyribonucleate suppositories, rectal and vaginal
GB2542106A (en) * 2015-04-01 2017-03-15 Nordic Labs Ltd Novel treatment of STIs
RU2601893C1 (en) * 2015-11-30 2016-11-10 Всеволод Иванович Киселев Drug preparation based on indole-3-carbinol with increased epigenetic activity
WO2017200413A1 (en) * 2016-05-16 2017-11-23 Нордик Лабз Лимитед Means for treating sexually-transmitted infectious diseases
CN108969602A (en) * 2018-09-29 2018-12-11 南京依美生物科技有限公司 It is a kind of to treat the Chinese medicine composition and preparation method that human papilloma virus sun is turned out cloudy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1275905B1 (en) * 1995-03-14 1997-10-24 Indena Spa POLYPHENOLIC FRACTIONS OF TEA, THEIR USE AND FORMULATIONS THAT CONTAIN THEM
RU2196568C1 (en) * 2001-08-08 2003-01-20 Киселев Всеволод Иванович Pharmaceutical composition for prophylaxis and treatment of uterus cervix dysplasia and cancer and larynx papillomatosis and method of prophylaxis and treatment of said sicknesses based on thereof
BR0302672A (en) * 2002-01-11 2004-02-25 Matthias Rath Nutrient pharmaceutical formulation comprising polyphenols and their uses in cancer treatment
RU2318510C1 (en) * 2006-04-19 2008-03-10 Всеволод Иванович Киселев 3,3'-diindolylmethane (metindol)-base vaginal suppository
RU2315594C1 (en) * 2006-09-01 2008-01-27 Всеволод Иванович Киселев Anti-estrogenic and anti-proliferative agent for treatment and prophylaxis of female reproductive system diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2456987C1 (en) * 2011-03-21 2012-07-27 Сергей Владимирович Енгашев Method for producing gelatine capsules of 3,31-diindolylmethane

Also Published As

Publication number Publication date
RU2395281C2 (en) 2010-07-27
EA201100417A1 (en) 2011-10-31
UA95583C2 (en) 2011-08-10
WO2010027294A1 (en) 2010-03-11
EA018383B1 (en) 2013-07-30

Similar Documents

Publication Publication Date Title
RU2008135764A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CERVICAL DYSPLASTIC PROCESSES
EA200601654A1 (en) HIV INTEGRASE INHIBITORS
DK1309589T3 (en) Urea Compounds and Methods of Use
NZ623495A (en) Oral formulations of cytidine analogs and methods of use thereof
UA90893C2 (en) Oral dosage forms of gemcitabine derivatives
MX2021002321A (en) Novel methods.
RU2010151631A (en) IRON BISGLYCINATE-CHELATE FOR USE IN ORAL TREATMENT OF ANEMIA IN PATIENTS WITH CELIACIA
RU2006113148A (en) VAGINAL SUPPOSITORIES BASED ON 3,3`-DIINDOLYLMETHANE (METHINDOL)
RU2013124416A (en) DIINDOLYLMETHANE MEDICINAL PRODUCT AND ITS APPLICATION FOR TREATMENT OF INFLUENZA AND RESPIRATORY VIRAL INFECTIONS
MX2023001301A (en) Antiviral use of liraglutide and gefitinib.
HRP20110370T1 (en) Use of agomelatine to obtain medication aimed at treating smith-magenis syndrome
RU2008115582A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PARKINSON'S DISEASE
RU2015114709A (en) STABLE INJECTION COMPOSITION CONTAINING DICLOFENAC AND THIOCOLCHICOSIDE
RU2012136190A (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF ARTHROZOARTHRITIS CONTAINING REBAMIPID AS AN ACTIVE INGREDIENT
RU2009133350A (en) APPLICATION OF CLAYS FOR TREATMENT OF DISEASES OF ABDOMINAL BODIES
MX2008011321A (en) Pharmaceutical composition for use in treating sexually transmitted infections.
RU2009142700A (en) ANTI-INFLAMMATORY AND ANTI-ALLERGIC MEDICINE AND PHARMACEUTICAL COMPOSITION ON ITS BASIS
AR046464A1 (en) MULTIPARTICLES OF CONTROLLED RELEASE WITH DISSOLUTION IMPROVERS
RU2544163C1 (en) Therapeutic agent in form of gel for treating herpetic infection manifestations in patients with burns and cold injuries
FR2871800B1 (en) SODIUM SALT S-TENATOPRAZOLE MONOHYDRATE AND THERAPEUTIC APPLICATION
RU2008149236A (en) PHARMACEUTICAL COMPOSITION HAVING ANTI-INFLAMMATORY AND ANTIBACTERIAL ACTION (OPTIONS)
RU2006109429A (en) CARSEL DRUG FOR PREVENTION AND TREATMENT OF OBSTETRIC AND GYNECOLOGICAL DISEASES IN COWS
RU2008139377A (en) SOLID DOSED MEDICINAL FOR TREATMENT OF DIABETES
RU2023132489A (en) LINE-1 INHIBITORS AS COGNITIVE FUNCTION ENHANCERS
RU2009124933A (en) Dense nutrient medium for the cultivation of mycobacteria isolated from leprosy patients with leprosy

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20180907